Last reviewed · How we verify
Bimatoprost 0.03% solution
Bimatoprost 0.03% solution is a Prostaglandin F analog Small molecule drug developed by Ahmed Hassan Nouh MD. It is currently FDA-approved for Open-angle glaucoma, Ocular hypertension. Also known as: Topical treatment of skin lesions, LUMIGAN®, Latisse®, LATISSE®.
Bimatoprost is a prostaglandin F analog that binds to prostaglandin F receptors to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.
Bimatoprost 0.03% solution is a small molecule that acts as a prostaglandin F2-alpha receptor agonist. It has been studied for various conditions, including glaucoma, open-angle glaucoma, and male pattern hair loss, among others.
At a glance
| Generic name | Bimatoprost 0.03% solution |
|---|---|
| Also known as | Topical treatment of skin lesions, LUMIGAN®, Latisse®, LATISSE®, Lumigan® |
| Sponsor | Ahmed Hassan Nouh MD |
| Drug class | Prostaglandin F analog |
| Target | Prostaglandin F receptor (FP receptor) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Bimatoprost mimics the action of prostaglandin F by activating F-prostanoid receptors in the eye. This activation enhances drainage of aqueous humor through the uveoscleral (unconventional) pathway, leading to decreased intraocular pressure. The drug is selective for prostaglandin F receptors and does not significantly activate other prostaglandin receptor subtypes.
Approved indications
- Open-angle glaucoma
- Ocular hypertension
Common side effects
- Increased iris pigmentation
- Eyelash growth (hypertrichosis)
- Conjunctival hyperemia
- Eye irritation/discomfort
- Darkening of periocular skin
Key clinical trials
- Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma (PHASE4)
- Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata (PHASE1, PHASE2)
- Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Topical Bimatoprost for Chemical Blepharoplasty (EARLY_PHASE1)
- Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose (PHASE4)
- Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension (PHASE1, PHASE2)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis (PHASE3)
- Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bimatoprost 0.03% solution CI brief — competitive landscape report
- Bimatoprost 0.03% solution updates RSS · CI watch RSS
- Ahmed Hassan Nouh MD portfolio CI
Frequently asked questions about Bimatoprost 0.03% solution
What is Bimatoprost 0.03% solution?
How does Bimatoprost 0.03% solution work?
What is Bimatoprost 0.03% solution used for?
Who makes Bimatoprost 0.03% solution?
Is Bimatoprost 0.03% solution also known as anything else?
What drug class is Bimatoprost 0.03% solution in?
What development phase is Bimatoprost 0.03% solution in?
What are the side effects of Bimatoprost 0.03% solution?
What does Bimatoprost 0.03% solution target?
Related
- Drug class: All Prostaglandin F analog drugs
- Target: All drugs targeting Prostaglandin F receptor (FP receptor)
- Manufacturer: Ahmed Hassan Nouh MD — full pipeline
- Therapeutic area: All drugs in Ophthalmology
- Indication: Drugs for Open-angle glaucoma
- Indication: Drugs for Ocular hypertension
- Also known as: Topical treatment of skin lesions, LUMIGAN®, Latisse®, LATISSE®, Lumigan®
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing